- Home
- IMCR vs VTLE Comparison
IMCR vs VTLE Comparison
Compare IMCR & VTLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VTLE
- Stock Information
- Founded
- IMCR 2008
- VTLE 2006
- Country
- IMCR United Kingdom
- VTLE United States
- Employees
- IMCR N/A
- VTLE N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VTLE
- Sector
- IMCR Health Care
- VTLE
- Exchange
- IMCR Nasdaq
- VTLE Nasdaq
- Market Cap
- IMCR 1.6B
- VTLE 640.1M
- IPO Year
- IMCR 2021
- VTLE 2011
- Fundamental
- Price
- IMCR $33.99
- VTLE $18.36
- Analyst Decision
- IMCR Buy
- VTLE Hold
- Analyst Count
- IMCR 10
- VTLE 11
- Target Price
- IMCR $58.13
- VTLE $26.38
- AVG Volume (30 Days)
- IMCR 422.6K
- VTLE 1.4M
- Earning Date
- IMCR 08-07-2025
- VTLE 08-06-2025
- Dividend Yield
- IMCR N/A
- VTLE N/A
- EPS Growth
- IMCR N/A
- VTLE N/A
- EPS
- IMCR N/A
- VTLE N/A
- Revenue
- IMCR $333,581,000.00
- VTLE $1,982,155,000.00
- Revenue This Year
- IMCR $26.82
- VTLE $3.26
- Revenue Next Year
- IMCR $8.15
- VTLE N/A
- P/E Ratio
- IMCR N/A
- VTLE N/A
- Revenue Growth
- IMCR 25.75
- VTLE 16.77
- 52 Week Low
- IMCR $23.15
- VTLE $12.30
- 52 Week High
- IMCR $41.54
- VTLE $47.80
- Technical
- Relative Strength Index (RSI)
- IMCR 56.49
- VTLE 54.11
- Support Level
- IMCR $32.20
- VTLE $16.22
- Resistance Level
- IMCR $33.95
- VTLE $19.05
- Average True Range (ATR)
- IMCR 1.22
- VTLE 1.05
- MACD
- IMCR 0.06
- VTLE -0.09
- Stochastic Oscillator
- IMCR 95.84
- VTLE 41.18
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.